Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Short Bowel Syndrome

ClinicalTrials.gov lists 158 trials for Short Bowel Syndrome or a narrower condition beneath it. Shire has the most among industry and government lead sponsors, with 15.

MeSH D012778 Digestive System Diseases C06 C23 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 32 Phase 4 Phase 4 13 Not applicable Not applicable 39 Observational Observational 37 Phase 1 Phase 1 8 Phase 1/2 Phase 1/2 5 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 32 Phase 4 Phase 4 13 Not applicable Not applicable 39 Observational Observational 37

Trials per phase

1 more section with rows

158 of the 158 trials are tagged with Short Bowel Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Short Bowel Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Short Bowel Syndrome trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 13

1996: 1 trials (Phase 2 1) 2003: 2 trials (Observational 1, Phase 4 1) 2004: 2 trials (Observational 1, Phase 3 1) 2005: 2 trials (Observational 1, Phase 3 1) 2006: 3 trials (Phase 4 1, Phase 3 1, Phase 2/3 1) 2007: 1 trials (Phase 1 1) 2008: 1 trials (Phase 3 1) 2009: 8 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1 3) 2010: 6 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1) 2011: 3 trials (Not applicable 1, Phase 2 1, Phase 1/2 1) 2012: 7 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1) 2013: 7 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 1) 2014: 6 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3) 2015: 7 trials (Observational 2, Not applicable 1, Phase 4 2, Phase 3 1, Phase 2/3 1) 2016: 8 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 1) 2017: 13 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 2) 2018: 13 trials (Observational 1, Not applicable 5, Phase 4 1, Phase 3 4, Phase 1/2 2) 2019: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 2020: 11 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 2 1, Phase 1/2 1) 2021: 13 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1 1) 2022: 10 trials (Observational 4, Not applicable 2, Phase 3 1, Phase 2 2, Phase 1 1) 2023: 6 trials (Observational 3, Not applicable 2, Phase 1 1) 2024: 4 trials (Not applicable 2, Phase 4 1, Phase 3 1) 2025: 8 trials (Observational 1, Not applicable 3, Phase 3 2, Phase 2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 8
2025 8
2024 4
2023 6
2022 10
2021 13
2020 11
2019 3
2018 13
2017 13

Showing 10 of 25 earlier years.

Start your 14-day trial Email me all 25 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 10 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 17 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 106 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Short Bowel Syndrome trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 8
Phase 1/2 5
Phase 2 17
Phase 2/3 3
Phase 3 32
Phase 4 13
Not applicable 39
Observational 37
Expanded access 4

How many Short Bowel Syndrome trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 2
Recruiting 18
Enrolling by invitation 3
Active, not recruiting 5
Completed 89

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Short Bowel Syndrome trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Shire 15
Takeda 10
Zealand Pharma 7
VectivBio AG 4
Chongqing Peg-Bio Biopharm Co., Ltd. 3

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Short Bowel Syndrome? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Glepaglutide 7
INTRALIPID 4
Glucagon like peptide-2 2
SOC 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
teduglutide 0.05 23
OMEGAVEN 10%® 8
Apraglutide 4
somatropin AQ 3
PJ009 2

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Short Bowel Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Device related infection 77 10
Pyrexia 76 12
Device breakage 28 10
Catheter sepsis 21 5
Influenza 21 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Short Bowel Syndrome? (185)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. Pediatrics international : official journal of the Japan Pediatric Society 2026 Yes
Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial. Gastroenterology 2025 Yes
Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure. Journal of pediatric gastroenterology and nutrition 2024 Yes
Glycemic and sleep effects of daytime compared with those of overnight infusions of home parenteral nutrition in adults with short bowel syndrome: A quasi-experimental pilot trial. The American journal of clinical nutrition 2024 Yes
Plasma metabolomics changes comparing daytime to overnight infusions of home parenteral nutrition in adult patients with short bowel syndrome: Secondary analysis of a clinical trial. Clinical nutrition ESPEN 2024 Yes

Showing 5 of 185 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Short bowel syndrome Point prevalence 1-9 / 100 000 Europe Not stated Exact
Short bowel syndrome Point prevalence 1-9 / 100 000 Europe Not stated Exact
Short bowel syndrome Point prevalence 1-9 / 100 000 Europe Not stated Unspecified

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Short bowel syndrome 104008 Exact Orphanet Rare Disease Ontology (ORDO)
Short bowel syndrome 104008 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages